D68.04
Acquired von Willebrand disease
Clinical Classification Guidelines
Inclusion Terms
- Acquired von Willebrand syndrome
Medical Intelligence & Overview
Acquired von Willebrand disease (VWD) is a rare bleeding disorder that occurs suddenly in individuals who previously had normal blood clotting. Unlike the inherited form of von Willebrand disease, which is present from birth, the acquired version develops later in life and is often linked to other medical conditions. It involves a deficiency or dysfunction of a protein called von Willebrand factor (vWF), which plays a crucial role in blood clotting. When vWF levels are abnormal, it can lead to problems with blood clot formation, causing abnormal bleeding episodes. Understanding this condition can help in recognizing its symptoms, causes, and available management strategies.
Causes & Symptoms
Clinical Causes: Underlying autoimmune disorders, where the body's immune system attacks vWF Certain types of cancers, including lymphomas and other hematologic malignancies Blood disorders such as myeloproliferative diseases Use of certain medications that affect blood clotting, like some anticoagulants or antiplatelet agents Severe cardiovascular diseases and conditions involving abnormal blood flow Other medical conditions such as hypothyroidism or some forms of cancer
Key Symptoms: Bleeding that is excessive or unusual, including nasal bleeding (epistaxis) Prolonged bleeding from cuts or injuries Bleeding gums or oral mucosa Heavy or prolonged menstruation in women Bleeding into joints or muscles, which can cause swelling or pain Frequent bruising In some cases, bleeding may be severe enough to cause life-threatening hemorrhages
Diagnostic & Treatment
Diagnosis Path: The diagnosis of acquired von Willebrand disease involves a combination of medical history review, physical examination, and laboratory tests. These tests typically include measurements of von Willebrand factor antigen levels, vWF activity, and factor VIII activity. Additional tests like platelet function analysis and bleeding time may also be performed to evaluate bleeding risk and confirm the diagnosis. Since acquired VWD is often associated with other health conditions, a comprehensive assessment of the patient's overall health and underlying disorders is essential.
Treatment Protocols: Replacement therapy with von Willebrand factor concentrates or cryoprecipitate to replenish deficient proteins during bleeding episodes or prior to invasive procedures Use of desmopressin (DDAVP) in selected cases, which stimulates the release of vWF from storage sites in blood vessels Treating underlying conditions such as cancers or autoimmune diseases to reduce their impact on vWF levels Adjusting or stopping medications that may worsen bleeding risk, under medical supervision Regular monitoring of vWF levels and blood clotting parameters to guide therapy
Clinical Advice & FAQs
Billing Guidance
Is D68.04 a billable ICD-10 code?
Yes, D68.04 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D68.04?
Clinical documentation must specify the nature of Acquired von Willebrand disease and any associated comorbidities for accurate reporting.
Cite this Clinical Reference